Correlation of activated STAT3 expression with clinicopathologic features in lung adenocarcinoma and squamous cell carcinoma (Q39669033)

13 September 2017

title

Correlation of activated STAT3 expression with clinicopathologic features in lung adenocarcinoma and squamous cell carcinoma (English)

1 reference

13 September 2017

1 reference

Richeng Jiang

1

1 reference

13 September 2017

Ziliang Jin

2

1 reference

13 September 2017

Zhujun Liu

3

1 reference

13 September 2017

Leina Sun

4

1 reference

13 September 2017

Liuchun Wang

5

1 reference

13 September 2017

Kai Li

6

1 reference

13 September 2017

publication date

1 December 2011

1 reference

Molecular Diagnosis and Therapy

13 September 2017

published in

1 reference

13 September 2017

volume

15

1 reference

13 September 2017

issue

6

1 reference

13 September 2017

page(s)

347-352

1 reference

https://scigraph.springernature.com/pub.10.1007/bf03256470

13 September 2017

exact match

0 references

cites work

Non–Small Cell Lung Cancer

1 reference

https://api.crossref.org/works/10.1007%2FBF03256470

Untangling the ErbB signalling network

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256470

Activation state EGFR and STAT-3 as prognostic markers in resected non-small cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256470

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256470

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256470

Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256470

Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256470

EGFR mutation and resistance of non-small-cell lung cancer to gefitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256470

Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256470

Kinase-driven pathways of EGFR in lung carcinomas: perspectives on targeting therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256470

Activation of Stat3 by receptor tyrosine kinases and cytokines regulates survival in human non-small cell carcinoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256470

Constitutive activation of stat 3 oncogene product in human ovarian carcinoma cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256470

Activated signal transducer and activator of transcription 3 (STAT3) supports the malignant phenotype of human pancreatic cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256470

STAT signaling in head and neck cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256470

New and old functions of STAT3: a pivotal target for individualized treatment of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256470

The STATs of cancer--new molecular targets come of age

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256470

EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256470

Activated epidermal growth factor receptor-Stat-3 signaling promotes tumor survival in vivo in non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256470

Tissue micro array analysis of ganglioside N-glycolyl GM3 expression and signal transducer and activator of transcription (STAT)-3 activation in relation to dendritic cell infiltration and microvessel density in non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256470

Signal transducer and activator of transcription 3 is required for the oncogenic effects of non-small-cell lung cancer-associated mutations of the epidermal growth factor receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256470

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256470

Mutations in the EGFR kinase domain mediate STAT3 activation via IL-6 production in human lung adenocarcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256470

Expression of p-STAT3 in human colorectal adenocarcinoma and adenoma; correlation with clinicopathological factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256470

Expression of activated signal transducer and activator of transcription-3 predicts poor prognosis in cervical squamous-cell carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256470

The Catalogue of Somatic Mutations in Cancer (COSMIC)

21 January 2018

1 reference

12 December 2020

Comparison of KRAS and EGFR gene status between primary non-small cell lung cancer and local lymph node metastases: implications for clinical practice

1 reference

12 December 2020

Expression of epidermal growth factor receptor (EGFR) and downstream-activated peptides in surgically excised non-small-cell lung cancer (NSCLC)

1 reference

12 December 2020

EGFR dependent expression of STAT3 (but not STAT1) in breast cancer

1 reference

12 December 2020

Identifiers

DOI

10.1007/BF03256470

1 reference

13 September 2017

1 reference